Labgenomics Co

Labgenomics Co EPS Growth

The EPS Growth of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is -170.53 %. In the previous year, EPS Growth was -409.12 % — a change of -58.32% (higher).

EPS Growth

-170.53 %

YoY

-58.32%

Last updated:

EPS Growth of Labgenomics Co is 2025 -170.53 % . EPS Growth of Labgenomics Co was 2024 -409.12 % . It decreases by -58.32% higher compared to the previous year.

The Labgenomics Co EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
-8.48 KRW
Jan 1, 2019
124.23 KRW
Jan 1, 2020
4,343.63 KRW
Jan 1, 2021
96.08 KRW
Jan 1, 2022
-42.28 KRW
Jan 1, 2023
-109.66 KRW
Jan 1, 2024
-409.12 KRW
Jan 1, 2025
-170.53 KRW
The Labgenomics Co EPS Growth history
YEAREPS GrowthYoY
-170.53 %-58.32%
-409.12 %+273.09%
-109.66 %+159.33%
-42.28 %-144.01%
96.08 %-97.79%
4,343.63 %+3,396.58%
124.23 %-1,564.96%
-8.48 %-98.60%
-606.18 %+991.94%
-55.51 %+69.26%
-32.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

EPS Growth of Labgenomics Co is -170.53 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Labgenomics Co

All Key Metrics — Labgenomics Co